

Catherine Sautes-fridman

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8011926/catherine-sautes-fridman-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

167
papers

19,142
citations

70
h-index

137
g-index

192
ext. papers

25,034
ext. citations

8.9
avg, IF

6.83
L-index

#	Paper	IF	Citations
167	C1q+ macrophages: passengers or drivers of cancer progression.. <i>Trends in Cancer</i> , 2022 ,	12.5	2
166	Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer.. <i>Immunity</i> , 2022 ,	32.3	11
165	Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.. <i>Lancet Oncology</i> , 2022 ,	21.7	6
164	B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome.. <i>Nature Reviews Clinical Oncology</i> , 2022 ,	19.4	7
163	Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study 2022 , 10, e004885		0
162	B cells and cancer: To B or not to B?. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	25
161	Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021 , 11, 643065	5.3	6
160	PD1 inhibition in soft-tissue sarcomas with tertiary lymphoid structures: A multicenter phase II trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 11507-11507	2.2	4
159	Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade. <i>Cancer Immunology Research</i> , 2021 , 9, 909-925	12.5	7
158	Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. <i>Cancer Immunology Research</i> , 2021 , 9, 891-908	12.5	7
157	Complement Detection in Human Tumors by Immunohistochemistry and Immunofluorescence. <i>Methods in Molecular Biology</i> , 2021 , 2227, 191-203	1.4	2
156	Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade. <i>Clinical Cancer Research</i> , 2021 ,	12.9	10
155	Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression.. <i>Nature Cancer</i> , 2021 , 2, 794-802	15.4	19
154	LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial. <i>Annals of Oncology</i> , 2020 , 31, S1157	10.3	19
153	7000 Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N). <i>Annals of Oncology</i> , 2020 , 31, S553	10.3	4
152	Complement System: Promoter or Suppressor of Cancer Progression?. <i>Antibodies</i> , 2020 , 9,	7	13
151	B cells and complement at the forefront of chemotherapy. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 393-394	19.4	2

150	The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. <i>Frontiers in Immunology</i> , 2020 , 11, 784	8.4	98
149	B cells are associated with survival and immunotherapy response in sarcoma. <i>Nature</i> , 2020 , 577, 556-560	50.4	538
148	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020 , 577, 549-555	50.4	654
147	Side-by-side comparison of flow cytometry and immunohistochemistry for detection of calreticulin exposure in the course of immunogenic cell death. <i>Methods in Enzymology</i> , 2020 , 632, 15-25	1.7	1
146	Early Hepatic Lesions Display Immature Tertiary Lymphoid Structures and Show Elevated Expression of Immune Inhibitory and Immunosuppressive Molecules. <i>Clinical Cancer Research</i> , 2020 , 26, 4381-4389	12.9	21
145	Therapeutic Targeting of the Colorectal Tumor Stroma. <i>Gastroenterology</i> , 2020 , 158, 303-321	13.3	23
144	The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression. <i>Genome Medicine</i> , 2020 , 12, 86	14.4	17
143	Dendritic cells in the tumor microenvironment: prognostic and theranostic impact. <i>Seminars in Immunology</i> , 2020 , 48, 101410	10.7	15
142	Tertiary Lymphoid Structures and B cells: Clinical impact and therapeutic modulation in cancer. <i>Seminars in Immunology</i> , 2020 , 48, 101406	10.7	13
141	M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer 2020 , 8,		23
140	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). <i>European Journal of Immunology</i> , 2019 , 49, 1457-1973	6.1	485
139	Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e981-e994	3.3	22
138	Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth. <i>Cancer Immunology Research</i> , 2019 , 7, 1091-1105	12.5	68
137	Tertiary lymphoid structures in the era of cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2019 , 19, 307-325	32.5	397
136	Revisiting immune escape in colorectal cancer in the era of immunotherapy. <i>British Journal of Cancer</i> , 2019 , 120, 815-818	8.7	13
135	NIVOREN GETUG-AFU 26 translational study: CD8 infiltration and PD-L1 expression are associated with outcome in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N). <i>Annals of Oncology</i> , 2019 , 30, v360-v361	10.3	2
134	Context-dependent roles of complement in cancer. <i>Nature Reviews Cancer</i> , 2019 , 19, 698-715	31.3	99
133	Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial. <i>Clinical Cancer Research</i> , 2019 , 25, 7351-7362	12.9	33

132	Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019 , 70, 58-65	13.4	86
131	The clinical role of the TME in solid cancer. <i>British Journal of Cancer</i> , 2019 , 120, 45-53	8.7	155
130	Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019 , 474, 463-474	5.1	12
129	Association of IL-36 with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 109-120	7.4	37
128	PD-L1 Expression and CD8 T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer. <i>European Urology Focus</i> , 2019 , 5, 192-196	5.1	60
127	Site-specific N-glycosylation analysis of soluble Fcγ receptor IIIb in human serum. <i>Scientific Reports</i> , 2018 , 8, 2719	4.9	18
126	The Human Tumor Microenvironment 2018 , 5-21		1
125	Immune-based identification of cancer patients at high risk of progression. <i>Current Opinion in Immunology</i> , 2018 , 51, 97-102	7.8	12
124	Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 981-988	7.4	58
123	Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients 2018 , 6, 139		66
122	Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine. <i>Frontiers in Oncology</i> , 2018 , 8, 390	5.3	31
121	Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017 , 23, 4416-4428	12.9	174
120	The immune contexture in cancer prognosis and treatment. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 717-734	19.4	935
119	Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models. <i>Journal of Visualized Experiments</i> , 2016 ,	1.6	13
118	Cancer immune contexture and immunotherapy. <i>Current Opinion in Immunology</i> , 2016 , 39, 7-13	7.8	93
117	Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. <i>Clinical Cancer Research</i> , 2016 , 22, 4057-66	12.9	306
116	Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. <i>Advances in Immunology</i> , 2016 , 130, 95-190	5.6	120
115	Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis. <i>Cancer Research</i> , 2016 , 76, 1746-56	10.1	122

114	Trial Watch-Oncolytic viruses and cancer therapy. <i>OncolImmunology</i> , 2016 , 5, e1117740	7.2	76
113	TLS in Tumors: What Lies Within. <i>Trends in Immunology</i> , 2016 , 37, 1-2	14.4	18
112	Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention. <i>Frontiers in Immunology</i> , 2016 , 7, 407	8.4	154
111	Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. <i>Immunological Reviews</i> , 2016 , 271, 260-75	11.3	167
110	Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. <i>Genome Biology</i> , 2016 , 17, 218	18.3	791
109	Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 3031-40	12.9	249
108	Mouse models of primary central nervous system lymphomas: tools for basing funding and therapeutic strategies. <i>Journal of Neuro-Oncology</i> , 2015 , 121, 9-18	4.8	4
107	The immune response in cancer: from immunology to pathology to immunotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015 , 467, 127-35	5.1	42
106	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. <i>OncolImmunology</i> , 2015 , 4, e1008866	7.2	162
105	Tumor Immunology, toward a Success Story?. <i>Frontiers in Immunology</i> , 2015 , 6, 65	8.4	1
104	Jejunal T Cell Inflammation in Human Obesity Correlates with Decreased Enterocyte Insulin Signaling. <i>Cell Metabolism</i> , 2015 , 22, 113-24	24.6	96
103	Profiling of the three circulating monocyte subpopulations in human obesity. <i>Journal of Immunology</i> , 2015 , 194, 3917-23	5.3	64
102	Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. <i>Clinical Cancer Research</i> , 2015 , 21, 1329-39	12.9	172
101	Trial watch: Naked and vectored DNA-based anticancer vaccines. <i>OncolImmunology</i> , 2015 , 4, e1026531	7.2	22
100	The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 191, 377-90	10.2	140
99	Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). <i>OncolImmunology</i> , 2015 , 4, e1049804	7.2	34
98	Trial Watch: Peptide-based anticancer vaccines. <i>OncolImmunology</i> , 2015 , 4, e974411	7.2	81
97	The immune contexture of primary and metastatic human tumours. <i>Current Opinion in Immunology</i> , 2014 , 27, 8-15	7.8	85

96	TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer. <i>Cancer Research</i> , 2014 , 74, 5008-18	10.1	64
95	Trial Watch: Chemotherapy with immunogenic cell death inducers. <i>OncolImmunology</i> , 2014 , 3, e27878	7.2	116
94	Tertiary lymphoid structures in cancer and beyond. <i>Trends in Immunology</i> , 2014 , 35, 571-80	14.4	288
93	Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014 , 189, 832-44	10.2	340
92	Shaping of an effective immune microenvironment to and by cancer cells. <i>Cancer Immunology, Immunotherapy</i> , 2014 , 63, 991-7	7.4	25
91	The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort. <i>Chest</i> , 2014 , 146, 633-643	5.3	70
90	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014 , 5, 12472-508	3.3	301
89	Tertiary lymphoid structures in human lung cancers, a new driver of antitumor immune responses. <i>OncolImmunology</i> , 2014 , 3, e28976	7.2	19
88	Trial Watch: Toll-like receptor agonists in oncological indications. <i>OncolImmunology</i> , 2014 , 3, e29179	7.2	61
87	Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. <i>OncolImmunology</i> , 2014 , 3, e27048.2	7.2	64
86	Trial watch: IDO inhibitors in cancer therapy. <i>OncolImmunology</i> , 2014 , 3, e957994	7.2	166
85	The immune microenvironment: a major player in human cancers. <i>International Archives of Allergy and Immunology</i> , 2014 , 164, 13-26	3.7	49
84	Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. <i>Cancer Research</i> , 2014 , 74, 705-15	10.1	306
83	The immune microenvironment of human tumors: general significance and clinical impact. <i>Cancer Microenvironment</i> , 2013 , 6, 117-22	6.1	93
82	Lymphoma B-cell responsiveness to CpG-DNA depends on the tumor microenvironment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013 , 32, 18	12.8	9
81	Characteristics of tertiary lymphoid structures in primary cancers. <i>OncolImmunology</i> , 2013 , 2, e26836	7.2	86
80	Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. <i>Clinical Cancer Research</i> , 2013 , 19, 4079-91	12.9	213
79	Trial watch: Monoclonal antibodies in cancer therapy. <i>OncolImmunology</i> , 2013 , 2, e22789	7.2	76

78	Trial Watch: Peptide vaccines in cancer therapy. <i>Oncolimmunology</i> , 2013 , 2, e26621	7.2	84
77	Trial Watch: Anticancer radioimmunotherapy. <i>Oncolimmunology</i> , 2013 , 2, e25595	7.2	75
76	Trial Watch: Toll-like receptor agonists for cancer therapy. <i>Oncolimmunology</i> , 2013 , 2, e25238	7.2	120
75	Trial watch: Oncolytic viruses for cancer therapy. <i>Oncolimmunology</i> , 2013 , 2, e24612	7.2	94
74	Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas 2013 , 54, 3657-65		27
73	Cytokine profile in human eyes: contribution of a new cytokine combination for differential diagnosis between intraocular lymphoma or uveitis. <i>PLoS ONE</i> , 2013 , 8, e52385	3.7	43
72	Lung tumor microenvironment induces specific gene expression signature in intratumoral NK cells. <i>Frontiers in Immunology</i> , 2013 , 4, 19	8.4	48
71	Prognostic impact of vitamin B6 metabolism in lung cancer. <i>Cell Reports</i> , 2012 , 2, 257-69	10.6	100
70	A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. <i>Blood</i> , 2012 , 119, 4182-91	2.2	107
69	Trial watch: Dendritic cell-based interventions for cancer therapy. <i>Oncolimmunology</i> , 2012 , 1, 1111-1134	7.2	134
68	Trial Watch: Monoclonal antibodies in cancer therapy. <i>Oncolimmunology</i> , 2012 , 1, 28-37	7.2	80
67	Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. <i>Oncolimmunology</i> , 2012 , 1, 1323-1343	7.2	173
66	The immune contexture in human tumours: impact on clinical outcome. <i>Nature Reviews Cancer</i> , 2012 , 12, 298-306	31.3	2819
65	Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. <i>Journal of Immunology</i> , 2012 , 189, 3528-37	5.3	78
64	Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. <i>Oncolimmunology</i> , 2012 , 1, 894-907	7.2	163
63	Tumor microenvironment in NSCLC suppresses NK cells function. <i>Oncolimmunology</i> , 2012 , 1, 244-246	7.2	24
62	The European Academy of Tumor Immunology: Bridging fields, continents and generations. <i>Oncolimmunology</i> , 2012 , 1, 127-128	7.2	
61	Trial watch: Chemotherapy with immunogenic cell death inducers. <i>Oncolimmunology</i> , 2012 , 1, 179-188	7.2	86

60	Trial watch: Peptide vaccines in cancer therapy. <i>Onc Immunology</i> , 2012 , 1, 1557-1576	7.2	73
59	Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. <i>Onc Immunology</i> , 2012 , 1, 699-716	7.16	164
58	FADD protein release mirrors the development and aggressiveness of human non-small cell lung cancer. <i>British Journal of Cancer</i> , 2012 , 106, 1989-96	8.7	24
57	Murine models of B-cell lymphomas: promising tools for designing cancer therapies. <i>Advances in Hematology</i> , 2012 , 2012, 701704	1.5	50
56	Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models. <i>Frontiers in Immunology</i> , 2012 , 3, 98	8.4	9
55	Trial Watch: Adoptive cell transfer immunotherapy. <i>Onc Immunology</i> , 2012 , 1, 306-315	7.2	58
54	Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. <i>Journal of Autoimmunity</i> , 2011 , 36, 9-15	15.5	55
53	Prognostic and predictive impact of intra- and peritumoral immune infiltrates. <i>Cancer Research</i> , 2011 , 71, 5601-5	10.1	297
52	The immune microenvironments of lung and intraocular tumors. <i>Bulletin Du Cancer</i> , 2011 , 98, 58-61	2.4	2
51	The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. <i>Frontiers in Immunology</i> , 2011 , 2, 66	8.4	7
50	Th17 cells are involved in the local control of tumor progression in primary intraocular lymphoma. <i>PLoS ONE</i> , 2011 , 6, e24622	3.7	21
49	Immune adaptive microenvironment profiles in intracerebral and intrasplenic lymphomas share common characteristics. <i>Clinical and Experimental Immunology</i> , 2011 , 165, 329-37	6.2	9
48	Alternative complement pathway assessment in patients with atypical HUS. <i>Journal of Immunological Methods</i> , 2011 , 365, 8-26	2.5	119
47	Tumor microenvironment is multifaceted. <i>Cancer and Metastasis Reviews</i> , 2011 , 30, 13-25	9.6	86
46	Immune infiltration in human cancer: prognostic significance and disease control. <i>Current Topics in Microbiology and Immunology</i> , 2011 , 344, 1-24	3.3	126
45	CD14 ^{dim} CD16 ⁺ and CD14 ⁺ CD16 ⁺ monocytes in obesity and during weight loss: relationships with fat mass and subclinical atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011 , 31, 2322-30	9.4	170
44	Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. <i>Cancer Research</i> , 2011 , 71, 6391-9	10.1	196
43	Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. <i>Cancer Research</i> , 2011 , 71, 5412-22	10.1	302

42	Immune infiltration in human tumors: a prognostic factor that should not be ignored. <i>Oncogene</i> , 2010 , 29, 1093-102	9.2	725
41	Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. <i>Kidney International</i> , 2010 , 77, 339-49	9.9	131
40	Metastatic melanomas express inhibitory low affinity fc gamma receptor and escape humoral immunity. <i>Dermatology Research and Practice</i> , 2010 , 2010, 657406	2	13
39	Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. <i>Journal of Clinical Investigation</i> , 2010 , 120, 1285-97	15.9	153
38	The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. <i>Journal of Medical Genetics</i> , 2009 , 46, 447-50	5.8	132
37	Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. <i>Blood</i> , 2009 , 114, 2837-45	2.2	119
36	Characterization of immune functions in TRAF4-deficient mice. <i>Immunology</i> , 2008 , 124, 562-74	7.8	22
35	Animal models of intraocular lymphomas. <i>Ophthalmic Research</i> , 2008 , 40, 208-11	2.9	6
34	Anti-CD16 autoantibodies and delayed phagocytosis of apoptotic cells in primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2008 , 30, 238-45	15.5	27
33	Activation of human peripheral IgM+ B cells is transiently inhibited by BCR-independent aggregation of Fc gammaRIIB. <i>Journal of Immunology</i> , 2008 , 181, 5350-9	5.3	12
32	Selective expression of inhibitory Fcgamma receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular response. <i>International Journal of Cancer</i> , 2008 , 123, 2832-9	7.5	26
31	Impaired th1/tc1 cytokine production of tumor-infiltrating lymphocytes in a model of primary intraocular B-cell lymphoma. <i>Investigative Ophthalmology and Visual Science</i> , 2007 , 48, 3223-9		27
30	Hereditary complement C7 deficiency in nine families: subtotal C7 deficiency revisited. <i>European Journal of Immunology</i> , 2007 , 37, 1377-85	6.1	24
29	TRAF4 overexpression is a common characteristic of human carcinomas. <i>Oncogene</i> , 2007 , 26, 142-7	9.2	61
28	A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. <i>Blood</i> , 2006 , 107, 190-6	2.2	280
27	Fc gamma receptors and cancer. <i>Seminars in Immunopathology</i> , 2006 , 28, 321-8		11
26	Measles virus nucleoprotein induces cell-proliferation arrest and apoptosis through NTAIL-NR and NCORE-FcgammaRIIB1 interactions, respectively. <i>Journal of General Virology</i> , 2005 , 86, 1771-1784	4.9	59
25	FcgammaRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP). <i>Leukemia</i> , 2004 , 18, 2038-40	10.7	10

24	FcγRIIB is differentially expressed during B cell maturation and in B-cell lymphomas. <i>British Journal of Haematology</i> , 2004 , 124, 55-62	4.5	23
23	Fc gamma receptors. <i>Immunology Letters</i> , 2004 , 92, 199-205	4.1	78
22	Primary Central Nervous System Lymphomas (PCNSL) Are Distinct from Systemic DLBCL for Expression Pattern of Germinal Center and Activation B-Cell Markers. A GOELAMS Study.. <i>Blood</i> , 2004 , 104, 2264-2264	2.2	1
21	N-glycosylation profile of recombinant human soluble Fcγ receptor III. <i>Glycobiology</i> , 2002 , 12, 507-518	3.8	19
20	Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. <i>Blood</i> , 2002 , 99, 2114-21	2.2	266
19	Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. <i>Blood</i> , 2002 , 100, 3646-55	2.2	72
18	Modulation of tumor growth by inhibitory Fcγ receptor expressed by human melanoma cells. <i>Journal of Clinical Investigation</i> , 2002 , 110, 1549-1557	15.9	26
17	Modulation of tumor growth by inhibitory Fc(γ) receptor expressed by human melanoma cells. <i>Journal of Clinical Investigation</i> , 2002 , 110, 1549-57	15.9	10
16	Mannose receptor ligand-positive cells express the metalloprotease decysin in the B cell follicle. <i>Journal of Immunology</i> , 2001 , 167, 5052-60	5.3	29
15	Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines. <i>Journal of Immunology</i> , 2001 , 166, 531-7	5.3	200
14	Soluble CD16 inhibits CR3 (CD11b/CD18)-mediated infection of monocytes/macrophages by opsonized primary R5 HIV-1. <i>Journal of Immunology</i> , 2001 , 166, 3377-83	5.3	30
13	Association of FcγRII with low-density detergent-resistant membranes is important for cross-linking-dependent initiation of the tyrosine phosphorylation pathway and superoxide generation. <i>Journal of Immunology</i> , 2001 , 167, 5814-23	5.3	56
12	The structure of a human type III Fcγ receptor in complex with Fc. <i>Journal of Biological Chemistry</i> , 2001 , 276, 16469-77	5.4	286
11	Expression of low-affinity Fc gamma receptor by a human metastatic melanoma line. <i>Immunology Letters</i> , 2000 , 75, 1-8	4.1	10
10	Structural basis of the interaction between IgG and Fcγ receptors. <i>Journal of Molecular Biology</i> , 2000 , 295, 213-24	6.5	70
9	Crystal structure of the extracellular domain of a human Fc gamma RIII. <i>Immunity</i> , 2000 , 13, 387-95	32.3	80
8	Inhibition of human immunodeficiency virus transmission to CD4+ T cells after gene transfer of constitutively expressed interferon beta to dendritic cells. <i>Human Gene Therapy</i> , 2000 , 11, 1695-703	4.8	3
7	Presentation of antigen in immune complexes is boosted by soluble bacterial immunoglobulin binding proteins. <i>Journal of Experimental Medicine</i> , 1999 , 189, 1217-28	16.6	10

6	Regulation of production of soluble Fc gamma receptors type III in normal and pathological conditions. <i>Immunology Letters</i> , 1999 , 68, 125-34	4.1	34
5	Control of tumor development by intratumoral cytokines. <i>Immunology Letters</i> , 1999 , 68, 135-9	4.1	23
4	Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. <i>Cancer Research</i> , 1999 , 59, 3698-704	10.1	215
3	The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression		1
2	webMCP-counter: a web interface for transcriptomics-based quantification of immune and stromal cells in heterogeneous human or murine samples		1
1	Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. <i>Nature Medicine</i> ,	50.5	5